Key clinical point: Inhibition of MET and MEK appears to be a viable strategy for treatment of resistant epidermal growth factor receptor–mutant non–small cell lung cancer.

Major finding: In the dose-finding phase of the trial, the objective response rate was 42% for 36 patients treated with the combination either as a second- or third-line therapy, or following prior therapy for the EGFR T70M mutation. In the dose-expansion phase of the trial, the ORR was 34% for 47 patients treated regardless of mutational status.

Study details: A phase 1b trial arm with 36 patients in a dose-finding phase and 47 patients in a dose-expansion phase.

Disclosures: The TATTON trial was sponsored by AstraZeneca. Dr. Ramalingam reported receiving research support from the company and consulting/contracting with others. Dr. Herbst reported receiving research support from AstraZeneca, Eli Lilly, and Merck, and serving as a consultant for AstraZeneca, Eli Lilly, Genentech/Roche, Merck, NextCure, and Pfizer.